A5013712067- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Cells and Metastasis
- Skin and Cellular Biology Research
- Pancreatic and Hepatic Oncology Research
- Liver physiology and pathology
- Organ Transplantation Techniques and Outcomes
- Gallbladder and Bile Duct Disorders
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Tissue Engineering and Regenerative Medicine
- Pancreatic function and diabetes
- Electrospun Nanofibers in Biomedical Applications
- Pluripotent Stem Cells Research
- Viral-associated cancers and disorders
- Microtubule and mitosis dynamics
- Pediatric Hepatobiliary Diseases and Treatments
- Cancer Research and Treatments
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Multiple and Secondary Primary Cancers
- Pancreatitis Pathology and Treatment
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
- Cancer Mechanisms and Therapy
Kyoto University
2016-2025
Kyoto University Hospital
2018-2024
National Institute of Informatics
2019
Japan Science and Technology Agency
2019
Kyushu University
2019
Kansai Electric Power Hospital
2017
Kansai Electric Power (Japan)
2017
Kobe Medical Center
2014-2016
Hamamatsu Rosai Hospital
2002-2003
Abstract Purpose: Keratin 19 (K19) is a known marker of poor prognosis and invasion in human hepatocellular carcinoma (HCC). However, the relationship between K19 cancer stem cells (CSCs) unclear. Here, we determined whether can be used as new CSC therapeutic target HCC. Experimental Design: HCC cell lines were transfected with promoter–driven enhanced green fluorescence protein gene. characteristics, epithelial–mesenchymal transition (EMT), TGFb/Smad signaling examined FACS-isolated...
Objective: To evaluate the long-term outcomes of surgery for recurrent hepatocellular carcinoma (HCC). Background: HCC recurs with high incidence after liver resection. Little is known about patients undergoing HCC. Methods: Among 989 who underwent R0/R1 resection between 1995 and 2014, 676 exhibited recurrence were included. Repeat was performed in 128 (RS group), not remaining 548 (NS group). Prognostic value repeat evaluated by comparing survival (SAR) RS NS groups. Subgroup analyses...
Abstract The current lack of cancer stem cell (CSC) markers that are easily evaluated by blood samples prevents the establishment new therapeutic strategies in hepatocellular carcinoma (HCC). Herein, we examined whether sex determining region Y-box 9 (SOX9) represents a CSC marker and osteopontin (OPN) can be used as surrogate SOX9 HCC. In HCC lines transfected with promoter-driven enhanced green fluorescence protein gene, FACS-isolated + cells were capable self-renewal differentiation into...
In the era of multidisciplinary treatment strategy, resectability for hepatocellular carcinoma (HCC) should be defined. This study aimed to propose and validate a classification HCC.We proposed following three groups; resectable-(R), borderline resectable-(BR), unresectable (UR)-HCCs. Resectable two groups were sub-divided according value indocyanine green clearance remnant liver (ICG-Krem) presence macrovascular invasion (MVI); BR-HCC was defined as resectable HCCs with MVI and/or...
PURPOSE Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these histopathology residual tumors. PATIENTS AND METHODS The IMbrave150 study's atezo-bev group was analyzed. PR or SD per RECIST v1.1 lasting more than 6 months defined as durable. For histologic analysis, a comparable real-world from Japan Taiwan who had undergone...
Hepatocytes derived from human embryonic stem cells (hESCs) are a potential cell source for regenerative medicine. However, the definitive factors that responsible hepatic differentiation of hESCs remain unclear. We aimed to evaluate effects various extracellular matrixes and growth on endodermal optimize culture conditions induce hESCs. The transgene vector contained enhanced green fluorescent protein (EGFP) under control alpha-fetoprotein (AFP) enhancer/promoter was transfected into hESC...
Tissue decellularization produces a three-dimensional scaffold that can be used to fabricate functional liver grafts following recellularization. Inappropriate cell distribution and clotting during blood perfusion hinder the practical use of recellularized livers. Here we aimed establish seeding method for optimal parenchymal endothelial cells, evaluate effect sinusoidal cells (LSECs) in decellularized liver. Primary rat hepatocytes LSECs were seeded into whole-liver scaffolds via biliary...
Abstract A whole-organ regeneration approach, using a decellularised xenogeneic liver as scaffold for the construction of transplantable was recently reported. Deriving suitable scaffolds first step towards clinical application; however, effective recellularisation remains to be achieved. This report presents strategy improvement process, novel cell-seeding technique and cell source. We evaluated recellularised grafts repopulated through portal vein or biliary duct with mice adult...
Although the standard therapy for advanced-stage hepatocellular carcinoma (HCC) is systemic chemotherapy, combination of atezolizumab and bevacizumab (atezo + bev) with a high objective response rate may lead to conversion resection in patients initially unresectable HCC. This study aims evaluate efficacy atezo bev achieving surgery prolonged progression-free survival (PFS) HCC.The RACB prospective, single-arm, multicenter, phase II trial evaluating technically and/or oncologically The main...
Liver transplantation is currently the only curative therapy for end-stage liver failure; however, establishment of alternative treatments required owing to serious donor organ shortage. Here, we propose a novel model hybrid three-dimensional artificial livers using both human induced pluripotent stem cells (hiPSCs) and rat decellularized serving as scaffold. Rat harvesting decellularization were performed reported in our previous studies. The scaffold was recellularized with hiPSC-derived...
Abstract Aim Some patients undergoing liver resection for hepatocellular carcinoma (HCC) have poor outcomes. Therefore, we aimed to propose a new resectability classification with HCC. Methods We classified into three categories: resectable (R), borderline (BR), and unresectable (UR). Patients ( n = 409) who underwent hepatectomy HCC were assigned the non‐UR (R BR classes combined; 285) UR‐HCC 68; training cohort). Patient characteristics in BR‐HCC R‐HCC groups compared. The criteria tested...
ABSTRACT Background This study aimed to evaluate the outcomes and role of lymphadenectomy in hypervascular intrahepatic cholangiocarcinoma (ICC) quantified using arterial phase contrast‐enhanced computed tomography (CT). Methods Consecutive patients with mass‐forming (MF) or predominantly MF type ICC who underwent surgical resection from 2000 2019 were retrospectively analyzed. Using image late phase, CT‐vascularity was calculated by dividing CT value tumor (Hounsfield units) that liver...
521 Background: The IMbrave150 study showed that atezolizumab plus bevacizumab (atezo+bev) is superior to sorafenib in progression-free survival and overall survival, making it the recommended first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). RACB was scheduled evaluate efficacy of atezo+bev achieving conversion surgery initially HCC. This time, we report short-term outcomes study. Methods: prospective, single-arm, multicenter Phase II trial evaluates achieve...
The prognosis for unresectable perihilar cholangiocarcinoma (phCCA) is extremely poor. Liver transplantation in combination with neoadjuvant chemoradiation therapy has become the treatment of choice phCCA USA. In 2018, we launched a prospective study to evaluate safety and efficacy living donor liver (LDLT) phCCA. A total 10 patients were enrolled this between 2018 2024. Finally, five underwent LDLT after chemotherapy, radiation, staging laparotomy, while other dropped out protocol. median...
Abstract Purpose To explore factors influencing the prognosis in patients with borderline‐resectable hepatocellular carcinoma (BR‐HCC) undergoing surgery. Methods The clinical data of BR‐HCC according to definition Expert Consensus Statement 2023 were collected from board‐certified HPB training centers and analyzed detail. Results Data a total 1509 (BR1, n = 718 BR2, 791) who underwent surgery collected. 5‐year disease‐specific survival rate (DSS) 3‐year recurrence‐free (RFS) determined as...
Abstract Background There is no specific boundary for stratifying survival outcomes in patients with node‐positive intrahepatic cholangiocarcinoma (ICC). This study aimed to propose advanced nodal status ICC. Methods Data from pathologically confirmed ICC who underwent liver resection (LR) lymph node dissection (LND) 2000 2020 at three tertiary centers were retrospectively analyzed. The boundaries of regions and the yield that stratified overall (OS) evaluated. (LN) defined as follows:...
Abstract ESCs are a potential cell source for therapy. However, there is no evidence that transplantation using ESC-derived hepatocytes therapeutically effective. The main objective of this study was to assess the therapeutic efficacy endodermal cells into liver injury model. β-galactosidase-labeled mouse were differentiated α-fetoprotein (AFP)-producing cells. AFP-producing or transplanted transgenic mice expressed diphtheria toxin (DT) receptors under control an albumin enhancer/promoter....